Table 2 Distribution of clinical,... | American Society of Hematology

Table 2

Distribution of clinical, laboratory, and cytogenetic parameters between SPARC and TGFBI methylation groups

Characteristic	SPARC high (n = 29)	SPARC low (n = 130)	P	TGFBI high (n = 29)	TGFBI low (n = 130)	P
Age, y			.44			.62
Median	67	65		65	66
Range	39-79	41-85		50-82	39-85
Sex, % male	52	49	.84	48	48	1.0
Hemoglobin, g/dL, median	10.5	10.2	.19	10.5	10.3	.84
LDH, U/L, median; n = 102	372	329	.73	335	349	.93
Calcium, mmol/L, median	2.4	2.4	.40	2.4	2.4	.50
Creatinine, µmol/L, median	126	107	.21	117	106	.30
Albumin, g/L, median	32	35	.27	33	35	.26
B2M, mg/L, median; n=117	4.1	5.0	.81	5.2	4.8	1.0
Bone disease, %	69	70	1.0	62	72	.37
Cytogenetics, % (no.); n = 142
t(4;14)	14 (3/22)	10 (12/120)	.70	33 (8/24)	5.9 (7/118)	.001
del(17p)	0 (0/22)	6.7 (8/120)	.36	0 (0/24)	6.8 (8/118)	.35
t(14;16)	4.5 (1/22)	5.0 (6/120)	1.0	5.1 (1/24)	4.2 (6/118)	1.0
Gain 1q	46 (10/22)	28 (34/120)	.13	38 (9/24)	30 (35/118)	.47
ISS, % (no.); n = 117			.89*			.44*
1	21 (4/19)	16 (16/98)		5.6 (1/18)	19 (19/99)
2	37 (7/19)	41 (40/98)		44 (8/18)	39 (39/99)
3	42 (8/19)	43 (42/98)		50 (9/18)	41 (41/99)
Treatment, no. (arm A/B)†			.55*			.55*
Intense	14 (5/9)	71 (33/38)		14 (6/8)	71 (32/39)
Nonintense	15 (6/9)	59 (29/30)		15 (6/9)	59 (29/30)

Characteristic	SPARC high (n = 29)	SPARC low (n = 130)	P	TGFBI high (n = 29)	TGFBI low (n = 130)	P
Age, y			.44			.62
Median	67	65		65	66
Range	39-79	41-85		50-82	39-85
Sex, % male	52	49	.84	48	48	1.0
Hemoglobin, g/dL, median	10.5	10.2	.19	10.5	10.3	.84
LDH, U/L, median; n = 102	372	329	.73	335	349	.93
Calcium, mmol/L, median	2.4	2.4	.40	2.4	2.4	.50
Creatinine, µmol/L, median	126	107	.21	117	106	.30
Albumin, g/L, median	32	35	.27	33	35	.26
B2M, mg/L, median; n=117	4.1	5.0	.81	5.2	4.8	1.0
Bone disease, %	69	70	1.0	62	72	.37
Cytogenetics, % (no.); n = 142
t(4;14)	14 (3/22)	10 (12/120)	.70	33 (8/24)	5.9 (7/118)	.001
del(17p)	0 (0/22)	6.7 (8/120)	.36	0 (0/24)	6.8 (8/118)	.35
t(14;16)	4.5 (1/22)	5.0 (6/120)	1.0	5.1 (1/24)	4.2 (6/118)	1.0
Gain 1q	46 (10/22)	28 (34/120)	.13	38 (9/24)	30 (35/118)	.47
ISS, % (no.); n = 117			.89*			.44*
1	21 (4/19)	16 (16/98)		5.6 (1/18)	19 (19/99)
2	37 (7/19)	41 (40/98)		44 (8/18)	39 (39/99)
3	42 (8/19)	43 (42/98)		50 (9/18)	41 (41/99)
Treatment, no. (arm A/B)†			.55*			.55*
Intense	14 (5/9)	71 (33/38)		14 (6/8)	71 (32/39)
Nonintense	15 (6/9)	59 (29/30)		15 (6/9)	59 (29/30)

B2M, β2-microglobulin; LDH, lactate dehydrogenase.

Overall P value for the frequency of 3 ISS groups/2 treatment groups across the methylation groups.

Arm A: conventional arm without thalidomide; arm B: experimental arm with thalidomide (see Materials and methods section).